Literature DB >> 16848843

Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program.

Anne Helene Olsen1, Olorunsola F Agbaje, Jonathan P Myles, Elsebeth Lynge, Stephen W Duffy.   

Abstract

The goal of this research was to estimate the overdiagnosis at the first and second screens of the mammography screening program in Copenhagen, Denmark. This study involves a mammography service screening program in Copenhagen, Denmark, with 35,123 women screened at least once. We fit multistate models to the screening data, including preclinical incidence of progressive cancers and nonprogressive (i.e., overdiagnosed) cancers. We estimated mean sojourn time as 2.7 years (95% confidence interval [CI] 2.2-3.1) and screening test sensitivity as 100% (95% CI 99.8-100). Overdiagnosis was estimated to be 7.8% (95% CI 0.3-26.5) at the first screen and 0.5% (95% CI 0.02-2.1) at the second screen. This corresponds to 4.8% of all cancers diagnosed among participants during the first two invitation rounds and following intervals. A modest overdiagnosis was estimated for the Copenhagen screening program, deriving almost exclusively from the first screen. The CIs were very broad, however, and estimates from larger datasets are warranted.

Entities:  

Mesh:

Year:  2006        PMID: 16848843     DOI: 10.1111/j.1075-122X.2006.00272.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  28 in total

Review 1.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

Review 2.  Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.

Authors:  Ruth Etzioni; Roman Gulati; Leslie Mallinger; Jeanne Mandelblatt
Journal:  Ann Intern Med       Date:  2013-06-04       Impact factor: 25.391

3.  Comparison of mammography sensitivity after reduction mammoplasty targeting the glandular and fat tissue.

Authors:  Murat Çakır; Tevfik Küçükkartallar; Ahmet Tekin; Nebil Selimoğlu; Necdet Poyraz; Mehmet Metin Belviranlı; Adil Kartal
Journal:  Ulus Cerrahi Derg       Date:  2015-06-01

4.  Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials.

Authors:  Marc D Ryser; Roman Gulati; Marisa C Eisenberg; Yu Shen; E Shelley Hwang; Ruth B Etzioni
Journal:  Am J Epidemiol       Date:  2019-01-01       Impact factor: 4.897

Review 5.  Breast cancer screening with mammography.

Authors:  Bradford R Hirsch; Gary H Lyman
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

6.  Breast cancer incidence and overdiagnosis in Catalonia (Spain).

Authors:  Montserrat Martinez-Alonso; Ester Vilaprinyo; Rafael Marcos-Gragera; Montserrat Rue
Journal:  Breast Cancer Res       Date:  2010-08-03       Impact factor: 6.466

Review 7.  Screening for breast cancer: an update for the U.S. Preventive Services Task Force.

Authors:  Heidi D Nelson; Kari Tyne; Arpana Naik; Christina Bougatsos; Benjamin K Chan; Linda Humphrey
Journal:  Ann Intern Med       Date:  2009-11-17       Impact factor: 25.391

8.  Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program.

Authors:  Solveig Hofvind; Berta Geller; Pamela M Vacek; Steinar Thoresen; Per Skaane
Journal:  Eur J Epidemiol       Date:  2007-06-27       Impact factor: 8.082

9.  Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.

Authors:  Kevin C Oeffinger; Elizabeth T H Fontham; Ruth Etzioni; Abbe Herzig; James S Michaelson; Ya-Chen Tina Shih; Louise C Walter; Timothy R Church; Christopher R Flowers; Samuel J LaMonte; Andrew M D Wolf; Carol DeSantis; Joannie Lortet-Tieulent; Kimberly Andrews; Deana Manassaram-Baptiste; Debbie Saslow; Robert A Smith; Otis W Brawley; Richard Wender
Journal:  JAMA       Date:  2015-10-20       Impact factor: 56.272

Review 10.  Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends.

Authors:  Karsten Juhl Jørgensen; Peter C Gøtzsche
Journal:  BMJ       Date:  2009-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.